The Journal of Allergy and Clinical Immunology: In Practice
Clinical CommunicationsA case of aquagenic urticaria successfully treated with omalizumab
References (9)
- et al.
Aquagenic urticaria in twins
World Allergy Organ J
(2013) - et al.
Treatment with propranolol of 6 patients with idiopathic aquagenic pruritus
J Allergy Clin Immunol
(2011) - et al.
Evidence that water acts as a carrier for an epidermal antigen in aquagenic urticaria
J Am Acad Dermatol
(1986) - et al.
Aquagenic urticaria: report of a case and review of the literature
Ann Allergy Asthma Immunol
(1998)
Cited by (20)
Clinical and diagnostic features of 33 patients with aquagenic urticaria
2023, Journal of Allergy and Clinical Immunology: In PracticeA Systematic Review of Aquagenic Urticaria—Subgroups and Treatment Options
2022, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :The combination of 1stAH1 (cyproheptadine) with sertraline and methscopolamine bromide patch was used in 1 patient and led to complete control.51 In 2 cases who did not respond to the combination of 1stAH1 and 2ndAH1, omalizumab (300 mg every 4 weeks) was used in 1 patient and led to complete control after 2 injections.55 Stanozolol was applied in another patient with human immunodeficiency virus infection and reported complete control; however, his symptoms relapsed after discontinuation of stanozolol.2
A case of aquagenic urticaria with a brief review of the literature
2018, Dermatologica SinicaOmalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence
2018, Journal of Allergy and Clinical ImmunologyCitation Excerpt :The advanced search option was used with the terms “omalizumab” AND, for example, “cold urticaria” to encompass results from all fields. This was complemented by any additional published or in press evidence known to us at the time of publication (Table II).19,20,36-76 All publications have been included, regardless of whether the results were positive or negative, to present a fair and unbiased account of the available published evidence.
Management of chronic inducible urticaria according to the guidelines: A prospective controlled study
2017, Journal of Dermatological ScienceCitation Excerpt :In 2014, omalizumab was approved by the FDA for AH-refractory CSU patients [39,40] and it was recommended by JTFPP, EAACI/GA2LEN/EDF/WAO and BSACI guidelines due to its efficacy and safety [5,8,9]. Efficacy of omalizumab for CSU has been shown by placebo controlled clinical trials [39,40–45], while there are just case reports and case series in the literature for CIndU [11,17,46–50]. There are on-going trials evaluating the efficacy of omalizumab in different types of CIndU which have not been published yet [CUTEX (NCT01580592), UFO (NCT02169115), XOLUS (NCT02262130), CUN-OMAL-UCOL (NCT02012387)].
Omalizumab in the Treatment of Chronic Inducible Urticaria
2017, Actas Dermo-Sifiliograficas
Conflicts of interest: The authors declare that they have no relevant conflicts of interest.